This program is focused on developing mucoadhesive nanoparticles (MNPs) encapsulating Cyclosporine A for treatment of Dry Eye Syndrome (DES). Eye drop solutions are subjected to rapid tear turnover, effectively removing 98% of drugs from the eye within 5 minutes of administration. For the treatment of eye diseases, drugs must be administered frequently, which in turn increases undesirable side effects and lowers patient compliance. Using MNPs allows the drug to stay in contact with the eye for extended periods of time, thereby potentially mitigating toxicity and compliance issues. This program, led by Dr. Frank Gu (University of Waterloo, Ontario) has now been spun out into MyX Therapeutics; an AmorChem start-up company.